Non coding RNAs in head and neck squamous cell carcinoma (HNSCC): A clinical perspective

Anticancer Research

Volumn 34, Issue 12, 2014, Pages 6887-6896

  Denaro, Nerina ^a   Merlano, Marco Carlo ^a   Russi, Elvio Grazioso ^a   Nigro, Cristiana Lo ^a  

^a S Croce City Hospital   (Italy)

Author keywords

EGFR; Epidermal growth factor receptor; HDAC; Hystone deacetylases; Not reported.; NR

Indexed keywords

ANTAGOMIR; ANTINEOPLASTIC AGENT; BETA CATENIN; BIOLOGICAL MARKER; CETUXIMAB; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; ERLOTINIB; HYPOXIA INDUCIBLE FACTOR 1; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 107; MICRORNA 122; MICRORNA 124; MICRORNA 137; MICRORNA 144; MICRORNA 200; MICRORNA 205; MICRORNA 26A; MICRORNA 31; MICRORNA 375; MICRORNA 9; MIRAVIRSEN; MOLECULAR MARKER; PROTEIN KINASE B; PROTEIN KINASE C EPSILON; PROTEIN LET 7I; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; UNTRANSLATED RNA; TUMOR MARKER;

CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CELL PROLIFERATION; CPG ISLAND; DISTANT METASTASIS; DNA METHYLATION; DNA REPLICATION; DOUBLE STRANDED DNA BREAK; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LYMPH NODE METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROSTATE CANCER; REVIEW; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE; GENETICS; HEAD AND NECK NEOPLASMS; METABOLISM; MULTIMODALITY CANCER THERAPY; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PHYSIOLOGY; SMOKING;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; MICRORNAS; PAPILLOMAVIRUS INFECTIONS; RNA, LONG NONCODING; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 84918527961     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. Cancer J Clin 64: 9-29, 2014.
2. Denaro N, Russi EG, Adamo V and Merlano MC: State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013. Oncology 86: 212-229, 2014.
3. Allegra A, Alonci A, Campo S Penna G, Petrungaro A, Gerace D and Musolino C: Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer. Int J Oncol 41: 1897-1912, 2012.
4. Wu BH, Xiong XP, Jia J and Zhang WF: MicroRNAs: new actors in the oral cancer scene. Oral Oncol 47: 314-319, 2011.
5. Gutschner Tand Diederichs S: The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 9: 703-719, 2012.
6. Qiu MT, Hu JW, Yin R and Xu L: Long noncoding RNA: an emerging paradigm of cancer research. Tumor Biology 34: 613-620, 2013.
7. Brown CJ, Ballabio A, Rupert JL, Lafreniere RG, Grompe M, Tonlorenzi R and Willard HF: A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. Nature 349: 38-44, 1991.
8. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E and Chang HY: Functional demarcation of active and silent chromatin domains in human HOX Loci by noncoding RNAs. Cell 7: 1311-1323, 2007.
9. Kino T, Hurt DE, Ichijo T, Nader N and Chrousos GP: Noncoding RNA Gas5 is a growth arrest-and starvationassociated repressor of the glucocorticoid receptor. Science Signaling 107: 8, 2010.
10. Wang X, Arai S, Song X, Reichart D, Du K, Pascual G, Tempst P, Rosenfeld MG, Glass CK and Kurokawa R: Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature 454: 126-130, 2008.
11. Janiszewska J, Szaumkessel M and Szyfter K: microRNAs are important players in head and neck carcinoma: a review. Crit Rev Oncol Hematol 88: 716-728, 2013.
12. Yoon JH, Abdelmohsen K and Gorospe M: Functional interactions among microRNAs and long noncoding RNAs. Semin Cell Dev Biol Jun 2, pii: S1084-9521(14) 00170-0, 2014.
13. Pérez-Sayáns M, Pilar GD, Barros-Angueira F, Suáez-Peñranda JM, Fernández AC, Gándara-Rey JM and Garc-Garc A: Current trends in miRNAs and their relationship with oral squamous cell carcinoma. J Oral Pathol Med 41: 433-443, 2012.
14. Harris T, Jimenez L, Kawachi N Fan JB, Chen J, Belbin T, Ramnauth A, Loudig O, Keller CE, Smith R, Prystowsky MB, Schlecht NF, Segall JE and Childs G: Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am J Pathol 180: 917-928, 2012.
15. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT and Giaccia AJ: Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 35: 856-867, 2009.
16. Cohen EE, Zhu H, Lingen MW, Martin LE, Kuo WL, Choi EA, Kocherginsky M, Parker JS, Chung CH and Rosner MR: A feedforward loop involving protein kinase C alpha and microRNAs regulates tumor cell cycle. Cancer Res 69: 65-74, 2009.
17. Li J, Huang H, Sun L , Yang M, Pan C, Chen W, Wu D, Lin Z, Zeng C, Yao Y, Zhang P and Song E: miR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res 15: 3998-4008, 2009.
18. Avissar M, Christensen BC, Kelsey KT and Marsit CJ: microRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin Cancer Res 15: 2850-2855, 2009.
19. Hedbäck N, Jensen DH and Specht L: miR-21 expression in the tumor stroma of oral squamous cell carcinoma: an independent biomarker of disease free survival. PLoS One 9: e95193, 2014.
20. Kozaki K, Imoto I, Mogi S, Omura K and Inazawa J: Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 68: 2094-2105, 2008.
21. Yu T, Liu K, Wu Y and Fan J, Chen J, Li C, Yang Q and Wang Z: microRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/β-catenin signaling pathway. Oncogene Oct 21, 2013.
22. Ganci F, Sacconi A, Bossel Ben-Moshe N, Manciocco V, Sperduti I, Strigari L, Covello R, Benevolo M, Pescarmona E, Domany E, Muti P, Strano S, Spriano G, Fontemaggi G and Blandino G: Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. Ann Oncol 24: 3082-3088, 2013.
23. Kita Y, Vincent K, Natsugoe S, Berindan-Neagoe I and Calin GA: Epigenetically regulated microRNAs and their prospect in cancer diagnosis. Expert Rev Mol Diagn 14: 673-683, 2014.
24. Alajez NM, Shi W, Wong D, Lenarduzzi M, Waldron J, Weinreb I and Liu FF. Lin28b promotes head and neck cancer progression via modulation of the insulin-like growth factor survival pathway. Oncotarget 3: 1641-1652, 2012.
25. Yu L, Lu J, Zhang B, Liu X, Wang L, Li SY, Peng XH, Xu X, Tian WD and Li XP: miR-26a inhibits invasion and metastasis of nasopharyngeal cancer by targeting EZH2. Oncol Lett 5: 1223-1228, 2013.
26. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S and Purow B: microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68: 3566-3572, 2008.
27. Kalinowski FC, Giles KM, Candy PA, Ali A, Ganda C, Epis MR, Webster RJ and Leedman PJ: Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7. PLoS One 7: e47067, 2012.
28. Datta J, Smith A, Lang JC, Islam M, Dutt D, Teknos TN and Pan Q: MicroRNA-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase Cε. Oncogene 31: 4045-4553, 2012.
29. Kinoshita T, Nohata N, Hanazawa T, Kikkawa N, Yamamoto N, Yoshino H, Itesako T, Enokida H, Nakagawa M, Okamoto Y and Seki N: Tumour-suppressive microRNA-29s inhibit cancer cell migration and invasion by targeting laminin-integrin signalling in head and neck squamous cell carcinoma. Br J Cancer 109: 2636-2645, 2013.
30. Saito K, Inagaki K, Kamimoto T, Ito Y, Sugita T, Nakajo S, Hirasawa A, Iwamaru A, Ishikura T, Hanaoka H, Okubo K, Onozaki T and Zama T: MicroRNA-196a is a putative diagnostic biomarker and therapeutic target for laryngeal cancer. PLoS One 8: e71480, 2013.
31. Lu ZM, Lin YF, Jiang L, Chen LS, Luo XN, Song XH, Chen SH and Zhang SY: Microribonucleic acid expression profiling and bioinformatic target gene analyses in laryngeal carcinoma. Onco Targets Ther 7: 525-533, 2014.
32. Zhang T, Han G, Wang Y, Chen K and Sun Y: MicroRNA expression profiles in supraglottic carcinoma. Oncol Rep 31: 2029-2034, 2014.
33. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP and Wei WI: Mature miRNA184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 14: 2588-2592, 2008.
34. Liu CJ, Lin SC, Yang CC, Cheng HW and Chang KW: Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head Neck 34: 219-224, 2012.
35. Cheetham SW, Gruhl F, Mattick JS and Dinger ME: Long noncoding RNAs and the genetics of cancer. Br J Cancer 108: 2419-2425, 2013.
36. Lanz RB, McKenna NJ, Onate SA, Albrecht U, Wong J, Tsai SY, Tsai MJ and OMalley BW: A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 97: 17-27, 1999.
37. Chooniedass-Kothari S, Hamedani MK, Troup S, Hubé F and Leygue E: The steroid receptor RNA activator protein is expressed in breast tumor tissues. Int J Cancer 118: 1054-1059, 2006.
38. Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F and Williams GT: GAS5, a non-proteincoding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 28: 195-208, 2009.
39. Luke B and Lingner J: TERRA: telomeric repeat-containing RNA. EMBO J 28: 2503-2510, 2009.
40. Ji P, Diederichs S, Wang W, Bng S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H and Mler-Tidow C: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22: 8031-8041, 2003.
41. Yang Z and Wang L: Regulation of microRNA expression and function by nuclear receptor signaling. Cell Biosci 1: 31, 2011.
42. Li X, Wu Z, Mei Q, Li X, Guo M, Fu X and Han W: Long noncoding RNA HOTAIR, a driver of malignancy, predicts negative prognosis and exhibits oncogenic activity in oesophageal squamous cell carcinoma. Br J Cancer 109: 2266-2278, 2013.
43. Rossignol F, Vaché C and Clottes E: Natural antisense transcripts of hypoxia-inducible factor 1alpha are detected in different normal and tumour human tissues. Gene 299: 135-140, 2002.
44. Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L, Sesterhenn IA, Srikantan V, Moul JW and Srivastava S: Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene 23: 605-611, 2004.
45. Wang CM, Wu QQ, Li SQ, Chen FJ, Tuo L, Xie HW, Tong YS, Ji L, Zhou GZ, Cao G, Wu M, Lv J, Shi WH and Cao XF: Upregulation of the long non-coding RNA PlncRNA-1 promotes esophageal squamous carcinoma cell proliferation and correlates with advanced clinical stage. Dig Dis Sci 59: 591-597, 2014.
46. Shah TM, Patel AK, Bhatt VD, Tripathi AK, Shah S, Shankar V and Joshi CG: The landscape of alternative splicing in buccal mucosa squamous cell carcinoma. Oral Oncol 49: 604-610, 2013.
47. Jia LF, Wei SB, Gan YH, Guo Y, Gong K, Mitchelson K, Cheng J and Yu GY: Expression, regulation and roles of miR-26a and MEG3 in tongue squamous cell carcinoma. Int J Cancer Dec 16, 2013.
48. Fang Z, Wu L, Wang L, Yang Y, Meng Y and Yang H: Increased expression of the long non-coding RNA UCA1 in tongue squamous cell carcinomas: a possible correlation with cancer metastasis. Oral Surg Oral Med Oral Pathol Oral Radiol 117: 89-95, 2014.
49. Li D, Feng J, Wu T, Wang Y, Sun Y, Ren J and Liu M: Long intergenic noncoding RNA HOTAIR is overexpressed and regulates PTEN methylation in laryngeal squamous cell carcinoma. Am J Pathol 182: 64-70, 2013.
50. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA and Jones PA: Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatinmodifying drugs in human cancer cells. Cancer Cell 9: 435-443, 2006.
51. Clague J, Lippman SM, Yang H , Hildebrandt MA, Ye Y, Lee JJ and Wu X: Genetic variation in microRNA genes and risk of oral premalignant lesions. Mol Carcinog 49: 183-189, 2010.
52. Ryan BM, Robles AI and Harris CC: Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 10: 389-402, 2010.
53. Liu Z, Li G, Wei S, Niu J, El-Naggar AK, Sturgis EM and Wei Q: Genetic variants in selected pre-microRNA genes and the risk of squamous cell carcinoma of the head and neck. Cancer 116: 4753-4760, 2010.
54. Langevin SM, Stone RA, Bunker CH, Lyons-Weiler MA, LaFramboise WA, Kelly L, Seethala RR, Grandis JR, Sobol RW and Taioli E: microRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck. Cancer 117: 1454-1462, 2011.
55. Kita Y, Nishizono Y, Okumura H, Uchikado Y, Sasaki K, Matsumoto M, Setoyama T, Tanoue K, Omoto I, Mori S, Owaki T, Ishigami S, Nakagawa H, Tanaka F, Mimori K, Mori M and Natsugoe S: Clinical and biological impact of cyclin-dependent kinase subunit 2 in esophageal squamous cell carcinoma. Oncol Rep 31: 1986-1992, 2014.
56. Janssen HL, Kauppinen S and Hodges MR: HCV infection and miravirsen. N Engl J Med 369: 878, 2013.
57. Ogawa T, Furukawa T, Shiga K, Hashimoto S, Ogawa K, Kobayashi T and Horii A: A cDNA microarray analysis identifies 52 genes associated with cis-diamminedichloro-platinum susceptibility in head and neck squamous cell carcinoma cell lines. Eur Arch Otorhinolaryngol 267: 123-129, 2010.
58. Yu CC, Chen YW, Chiou GY , Tsai LL, Huang PI, Chang CY, Tseng LM, Chiou SH, Yen SH, Chou MY, Chu PY and Lo WL: microRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation. Oral Oncol 47: 202-210, 2011.
59. Yang H, Kong W, He L, Zhao JJ, ODonnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV and Cheng JQ: microRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68: 425-433, 2008.
60. Hebert C, Norris K, Scheper MA, Nikitakis N and Sauk JJ: High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 6: 5, 2007.
61. Dai Y, Xie CH, Neis JP, Fan CY, Vural E and Spring PM: microRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 33: 786-791, 2011.
62. Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, Pohlmann PR, Gilbert J, Murphy B, Yarbrough WG, Wheeler DL, Harari PM, Guo Y, Shyr Y, Slebos RJ and Chung CH: Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One 5: e12702, 2010.
63. Huang Y, Kesselman D, Kizub D, Guerrero-Preston R and Ratovitski EA: Phospho-δNp63α/microRNA feedback regulation in squamous carcinoma cells upon cisplatin exposure. Cell Cycle 12: 684-697, 2013.
64. Chen Z, Ma T, Huang C, Hu T and Li J: miR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells. Cell Signal 25: 2693-2701, 2013.
65. Summerer I, Niyazi M, Unger K, Pitea A, Zangen V, Hess J, Atkinson MJ, Belka C, Moertl S and Zitzelsberger H: Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients. Radiat Oncol 8: 296, 2013.
66. Xu CZ, Xie J, Jin B, Chen XW, Sun ZF, Wang BX and Dong P: Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line. Int J Clin Exp Pathol 6: 1351-1361, 2013.
67. Niemoeller OM, Niyazi M, Corradini S, Zehentmayr F, Li M, Lauber K and Belka C: microRNA expression profiles in human cancer cells after ionizing radiation.Radiat Oncol 6: 29, 2011.
68. Zhang B, Chen J, Ren Z, Chen Y, Li J, Miao X, Song Y, Zhao T, Li Y, Shi Y, Ren D and Liu J: A specific miRNA signature promotes radioresistance of human cervical cancer cells. Cancer Cell Int 13: 118, 2013.
69. Cortez MA, Valdecanas D, Zhang X, Zhan Y, Bhardwaj V, Calin GA, Komaki R, Giri DK, Quini CC, Wolfe T, Peltier HJ, Bader AG, Heymach JV, Meyn RE and Welsh JW: Therapeutic Delivery of miR-200c Enhances Radiosensitivity in Lung Cancer. Mol Ther 22: 1494-1503, 2014.
70. Tran N, McLean T, Zhang X , Zhao CJ, Thomson JM, OBrien C and Rose B: microRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun 358: 12-17, 2007.
71. Chang SS, Jiang WW, Smith I, Poeta LM, Begum S, Glazer C, Shan S, Westra W, Sidransky D and Califano JA: microRNA alterations in head and neck squamous cell carcinoma. Int J Cancer 123: 2791-2797, 2008.
72. Hui AB, Lenarduzzi M, Krushel T, Waldron L, Pintilie M, Shi W, Perez-Ordonez B, Jurisica I, OSullivan B, Waldron J, Gullane P, Cummings B and Liu FF: Comprehensive microRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res 16: 1129-1139, 2010.
73. Ramdas L, Giri U, Ashorn CL, Coombes KR, El-Naggar A, Ang KK and Story MD: miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue. Head Neck 31: 642-654, 2009.
74. Cervigne NK, Reis PP, Machado J, Sadikovic B, Bradley G, Galloni NN, Pintilie M, Jurisica I, Perez-Ordonez B, Gilbert R, Gullane P, Irish J and Kamel-Reid S: Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Hum Mol Genet 18: 4818-4829, 2009.
75. Liu X, Luo HN, Tian WD, Lu J, Li G, Wang L, Zhang B, Liang BJ, Peng XH, Lin SX, Peng Y and Li XP: Diagnostic and prognostic value of plasma microRNA deregulation in nasopharyngeal carcinoma. Cancer Biol Ther 14: 1133-1142, 2013.
76. Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E and Wong DT: Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 15: 5473-5477, 2009.
77. Childs G, Fazzari M, Kung G, Kawachi N, Brandwein-Gensler M, McLemore M, Chen Q, Burk RD, Smith RV, Prystowsky MB, Belbin TJ and Schlecht NF: Low-level expression of microRNAs let-7d and miRNA205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 174: 736-75, 2009.
78. Shi LJ, Zhang CY, Zhou ZT, Ma JY, Liu Y, Bao ZX and Jiang WW: microRNA-155 in oral squamous cell carcinoma: Overexpression, localization, and prognostic potential. Head Neck Apr 2, 2014.
79. Tian L, Li M, Ge J Guo Y, Sun Y, Liu M and Xiao H: miR-203 is downregulated in laryngeal squamous cell carcinoma and can suppress proliferation and induce apoptosis of tumours. Tumour Biol 35: 5953-5963, 2014.
80. Kikkawa N, Kinoshita T, Nohata N, Hanazawa T, Yamamoto N, Fukumoto I, Chiyomaru T, Enokida H, Nakagawa M, Okamoto Y and Seki N: microRNA-504 inhibits cancer cell proliferation via targeting CDK6 in hypopharyngeal squamous cell carcinoma. Int J Oncol 44: 2085-2092, 2014.